• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A case of anaphylaxis to alemtuzumab.

作者信息

Nye Charles J S, Wagner Annette, Kousin-Ezewu Onajite, Jones Joanne L, Coles Alasdair J

机构信息

University of Cambridge, Cambridge, UK.

Department of Allergy and Immunology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

出版信息

J Neurol. 2019 Mar;266(3):780-781. doi: 10.1007/s00415-019-09214-2. Epub 2019 Feb 4.

DOI:10.1007/s00415-019-09214-2
PMID:30715557
Abstract
摘要

相似文献

1
A case of anaphylaxis to alemtuzumab.1例对阿仑单抗过敏的病例。
J Neurol. 2019 Mar;266(3):780-781. doi: 10.1007/s00415-019-09214-2. Epub 2019 Feb 4.
2
Pulmonary embolism during the third cycle of alemtuzumab in a patient with relapsing multiple sclerosis.在接受来那度胺治疗的复发性多发性硬化症患者中，第 3 个周期时发生肺栓塞。
Mult Scler Relat Disord. 2019 Oct;35:5-6. doi: 10.1016/j.msard.2019.06.032. Epub 2019 Jun 29.
3
Acute coronary syndrome associated with alemtuzumab infusion in multiple sclerosis.与阿仑单抗输注相关的急性冠状动脉综合征在多发性硬化症中的情况
Neurology. 2018 May 1;90(18):852-854. doi: 10.1212/WNL.0000000000005417. Epub 2018 Mar 30.
4
Case of alemtuzumab-related alopecia areata management in MS.多发性硬化症中阿仑单抗相关斑秃的治疗病例
Neurol Neuroimmunol Neuroinflamm. 2018 Oct 19;6(1):e516. doi: 10.1212/NXI.0000000000000516. eCollection 2019 Jan.
5
Acute cardiotoxicity associated with alemtuzumab infusion for multiple sclerosis.与多发性硬化症用阿仑单抗输注相关的急性心脏毒性。
Mult Scler. 2020 May;26(6):735-737. doi: 10.1177/1352458519855725. Epub 2020 Apr 16.
6
Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis.阿仑单抗治疗多发性硬化症后侵袭性肺曲霉病的尸检诊断
Mult Scler. 2020 Jan;26(1):123-126. doi: 10.1177/1352458518813110. Epub 2019 Mar 18.
7
Disseminated necrotizing leukoencephalopathy eight months after alemtuzumab treatment for multiple sclerosis.阿仑单抗治疗多发性硬化症八个月后发生播散性坏死性白质脑病。
Acta Neuropathol Commun. 2016 Aug 8;4(1):81. doi: 10.1186/s40478-016-0352-1.
8
Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab.在使用阿仑单抗治疗多发性硬化症后，发生危及生命的自身免疫性温性溶血性贫血。
Mult Scler. 2018 May;24(6):811-813. doi: 10.1177/1352458517729766. Epub 2018 Jan 23.
9
Recurrent and universal alopecia areata following alemtuzumab treatment in multiple sclerosis: A secondary autoimmune disease.阿仑单抗治疗多发性硬化症后出现复发性和普遍性斑秃：一种继发性自身免疫性疾病。
Mult Scler Relat Disord. 2019 Jan;27:406-408. doi: 10.1016/j.msard.2018.12.005. Epub 2018 Dec 3.
10
A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS.1例接受阿仑单抗治疗的多发性硬化症患者发生特发性多中心Castleman病。
Neurol Neuroimmunol Neuroinflamm. 2019 Nov 8;7(1). doi: 10.1212/NXI.0000000000000638. Print 2020 Jan.

引用本文的文献

1
Dermatologic complications in transplantation and cellular therapy for acute leukemia.急性白血病移植和细胞治疗的皮肤并发症。
Best Pract Res Clin Haematol. 2023 Jun;36(2):101464. doi: 10.1016/j.beha.2023.101464. Epub 2023 Apr 6.
2
Successful Rapid Drug Desensitization with A Modified Protocol To Alemtuzumab in A Multiple Sclerosis Patient with Severe Immediate-Type Hypersensitivity Reaction.采用改良方案对一名患有严重速发型过敏反应的多发性硬化症患者成功进行阿仑单抗快速药物脱敏治疗。
Noro Psikiyatr Ars. 2022 Aug 16;59(3):237-241. doi: 10.29399/npa.27371. eCollection 2022.

本文引用的文献

1
Prevention and Management of Infusion-Associated Reactions in the Comparison of Alemtuzumab and Rebif(®) Efficacy in Multiple Sclerosis (CARE-MS) Program.在阿仑单抗与利比（Rebif®）治疗多发性硬化症疗效比较（CARE-MS）项目中输液相关反应的预防与管理
Int J MS Care. 2015 Jul-Aug;17(4):191-8. doi: 10.7224/1537-2073.2014-030.
2
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.阿仑单抗与干扰素β1a 作为复发缓解型多发性硬化症一线治疗的比较：一项随机对照 3 期试验。
Lancet. 2012 Nov 24;380(9856):1819-28. doi: 10.1016/S0140-6736(12)61769-3. Epub 2012 Nov 1.
3
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
阿仑单抗治疗缓解复发型多发性硬化症患者：一项疾病修饰治疗后随机对照 3 期试验。
Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1.
4
Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.阿仑单抗与干扰素β-1a治疗早期多发性硬化症的对比
N Engl J Med. 2008 Oct 23;359(17):1786-801. doi: 10.1056/NEJMoa0802670.
5
Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival.阿仑单抗治疗后B细胞慢性淋巴细胞白血病微小残留病的清除与生存期延长相关。
J Clin Oncol. 2005 May 1;23(13):2971-9. doi: 10.1200/JCO.2005.04.021. Epub 2005 Feb 28.
6
Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis.单克隆抗体治疗揭示了多发性硬化症临床病程背后的三种机制。
Ann Neurol. 1999 Sep;46(3):296-304. doi: 10.1002/1531-8249(199909)46:3<296::aid-ana4>3.0.co;2-#.
7
Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells.CAMPATH 1-H引发首剂细胞因子释放综合征的机制：自然杀伤细胞上CD16（FcγRIII）和CD11a/CD18（淋巴细胞功能相关抗原-1）的作用
J Clin Invest. 1996 Dec 15;98(12):2819-26. doi: 10.1172/JCI119110.